Navigation Links
Eurand's Zentase Effective in Treating Exocrine Pancreatic,Insufficiency, Studies Show

ics on the worldwide incidence of EPI, but in the U.S., it is estimated that more than 200,000 people suffer from EPI.

"Nutritional status, lung function and life expectancy are tightly connected in cystic fibrosis patients. In general, enhancing CFA and CNA levels improves nutrition. Good nutrition improves lung function. And, better lung function improves life expectancy," said James E. Heubi, MD, Director, General Clinical Research Center, Professor of Pediatrics, Cincinnati Children's Hospital Medical Center. "These data suggest that Zentase could provide EPI patients with an effective treatment option that would normalize CFA which could protect lung function and increase life expectancy."

Zentase is a zero-overfill, highly-stable, porcine-derived PEP. If approved by the FDA, it is expected to be available in four dose strengths, including a low-dose formulation for children that can be sprinkled on food.

"As a company, our goal is to develop products that optimize efficacy and tolerability while meeting patient needs for convenience, which is why we developed Zentase specifically with patients in mind," said Gearoid Faherty, Chief Executive Officer, Eurand. "The data presented in Turkey are an indication that with Zentase, we are well on the way toward meeting that goal."

About the Studies

The two phase III studies were designed to test Zentase in EPI patients presenting with the full range of disease severity. The studies included patients from 1-24 years of age with disease severity including mild, moderate and severe malabsorption. Half of the patients enrolled in the pivotal study had a baseline CFA greater than 65 percent and half had a baseline CFA lower than 65 percent (median CFA levels were 65.8 percent). Patients enrolled in the pivotal study had a wide range of baseline CFA levels with one patient as low as 28.7 percent (very severe disease) and five patients with CFA levels above 80 percent.

The majority of
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Eurand to Present Zentase Phase III Data
2. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
3. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
8. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
9. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
10. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
11. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015  OncoGenex Pharmaceuticals, Inc. ... report its second quarter 2015 financial results on Thursday, ... call and live webcast at 4:30 p.m. Eastern Time ... programs and a general corporate update. ... Relations page of the OncoGenex website at www.oncogenex.com ...
(Date:7/30/2015)... PLAINFIELD, N.J., July 30, 2015 PTC Therapeutics, ... update and reported financial results for the second quarter ... progressing on many fronts across the organization.  We are ... Duchenne muscular dystrophy clinical trial ever conducted with topline ... Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... MASI ) today announced that its management is scheduled ... The Pierre Hotel in New York on Tuesday, November 15, ... the presentation will be available on the Masimo website at ... available following the live presentation. About ...
... Nov. 8, 2011 ChemoCentryx, Inc., today announced that ... the Annual Meeting of the American College of Rheumatology ... targets and inhibits the chemokine receptor known as CCR1, ... rheumatoid arthritis (RA).  Results showed that CCX354 was safe ...
Cached Medicine Technology:Masimo to Present at Lazard Capital Markets Healthcare Conference 2ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 2ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 3ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 4
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On will ... October 3, 2015. The Ride to Fight On is a cycling fundraiser that benefits ... The West Clinic and The University of Tennessee Health Science Center. A health and ...
(Date:7/31/2015)... ... 31, 2015 , ... Coco Libre announced today that their flagship Organic Coconut ... 2015 Vans US Open of Surfing, July 25 through August 2 in Huntington Beach, ... on the market, is a natural choice given the Open’s commitment to sustainable practices. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique pastries ... wedding cakes with custom designs, making life just a little bit sweeter for ... cakes for each customer who orders one. , The bakery provides a full line ...
(Date:7/31/2015)... ... 2015 , ... Transfinder, a software company based in Schenectady, N.Y., achieved record ... year-over-year for the first six months ended June 30, 2015 compared with the same ... last year’s record-revenue mark of $10.4 million. , “We know what our customers need ...
(Date:7/31/2015)... NY (PRWEB) , ... July 31, 2015 , ... The ... marijuana, on research projects that evaluate the potential of related, experimental treatments. The collaboration ... Department of Health to award Columbia Care one of five state licenses to produce ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3
... students to benefit from program targeting kids in five-county ... American dream -- that children have more opportunities and ... at risk as the incidence of obesity among children ... could become the first in this country,s history to ...
... Andre Konski, M.D., M.B.A., has been offered ... Department of Radiation Oncology for the Wayne ... Chief for Radiation Oncology at the Barbara Ann ... Konski comes to Wayne State and ...
... Pierre,s Ice Cream Company, makers of,Hola Fruta!(R) ... innovation,called Yovation(TM). , (Photo: ... Yovation(TM) is a new premium, probiotic frozen ... and popularity of probiotic products and the,recognition by ...
... Plans Thousands of Franchisees Nationally With More than 1,800 ... eMed-ID, the world,s first medical identification franchise, announced today ... provides a personal USB device to consumers containing their ... for consumers to document their private medical history on ...
... Jan. 9 (HealthDay News) -- Parents may not always ... exercise habits, a new study shows. , Researchers reported ... Education and Behavior that mothers of preschool-aged children ... with older children did not. But when the children ...
... enhanced website designed to provide improved accessibility and ... Labs, a Zeus company, announces the launch of ... via the original URL and can be found ... with expanded content, including more information about Polymathic,s ...
Cached Medicine News:Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 2Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 3Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 4Health News:Andre Konski, M.D., M.B.A., Accepts Radiation Oncology Position at Wayne State University and the Karmanos Cancer Institute 2Health News:Andre Konski, M.D., M.B.A., Accepts Radiation Oncology Position at Wayne State University and the Karmanos Cancer Institute 3Health News:Standing Ovation for Pierre's New Innovation! 2Health News:Standing Ovation for Pierre's New Innovation! 3Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 2Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 3Health News:Parents Not Best Barometer of Kid's Eating, Exercise Habits 2Health News:Polymathic Analytical Labs Launches New Website 2
Multipiece PMMA IOL - Sulcus Fixation....
Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
Raysoft Foldable Intraocular Lens....
HAPTIBAG Hydrophilic Acrylic Lens....
Medicine Products: